Evofem Biosciences, Inc. (EVFM)
0.0071
0.00 (0.00%)
USD |
OTCM |
Sep 08, 16:00
Evofem Biosciences Enterprise Value : 60.01M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 60.01M |
| September 04, 2026 | 60.09M |
| September 03, 2026 | 60.06M |
| September 02, 2026 | 60.13M |
| September 01, 2026 | 60.13M |
| August 31, 2026 | 60.16M |
| August 28, 2026 | 60.06M |
| August 27, 2026 | 60.15M |
| August 26, 2026 | 60.11M |
| August 25, 2026 | 60.01M |
| August 24, 2026 | 59.99M |
| August 21, 2026 | 60.06M |
| August 20, 2026 | 60.10M |
| August 19, 2026 | 60.07M |
| August 18, 2026 | 60.13M |
| August 17, 2026 | 60.06M |
| August 14, 2026 | 60.06M |
| August 13, 2026 | 60.11M |
| August 12, 2026 | 60.02M |
| August 11, 2026 | 60.15M |
| August 10, 2026 | 60.02M |
| August 07, 2026 | 60.13M |
| August 06, 2026 | 60.19M |
| August 05, 2026 | 60.18M |
| August 04, 2026 | 60.02M |
| Date | Value |
|---|---|
| August 03, 2026 | 60.15M |
| July 31, 2026 | 59.99M |
| July 30, 2026 | 60.01M |
| July 29, 2026 | 60.07M |
| July 28, 2026 | 60.07M |
| July 27, 2026 | 60.11M |
| July 24, 2026 | 60.15M |
| July 23, 2026 | 60.18M |
| July 22, 2026 | 60.09M |
| July 21, 2026 | 60.13M |
| July 20, 2026 | 60.13M |
| July 17, 2026 | 60.09M |
| July 16, 2026 | 60.06M |
| July 15, 2026 | 60.13M |
| July 14, 2026 | 60.17M |
| July 13, 2026 | 60.18M |
| July 10, 2026 | 60.19M |
| July 09, 2026 | 60.31M |
| July 08, 2026 | 60.32M |
| July 07, 2026 | 60.35M |
| July 06, 2026 | 60.26M |
| July 02, 2026 | 60.13M |
| July 01, 2026 | 60.23M |
| June 30, 2026 | 60.12M |
| June 29, 2026 | 56.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.848B |
| Corcept Therapeutics, Inc. | 12.00B |
| Veru, Inc. | 20.88M |
| Johnson & Johnson | 676.38B |
| Eli Lilly & Co. | 1.104T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.04M |
| Revenue (Quarterly) | 2.633M |
| Total Expenses (Quarterly) | 13.67M |
| EPS Diluted (Quarterly) | -0.0811 |
| Gross Profit Margin (Quarterly) | 80.06% |
| Profit Margin (Quarterly) | -419.1% |
| Earnings Yield | -1.61K% |
| Normalized Earnings Yield | -1046.48 |